Minerva Neurosciences (NERV) Non-Current Debt (2015 - 2017)
Minerva Neurosciences' (NERV) quarterly Non-Current Debt came in at $1.3 million in Q2 2017, down 78.69% YoY from $6.2 million in Q2 2016, and down 48.99% on a QoQ basis from $2.6 million in Q1 2017.
Analysis
Minerva Neurosciences (NERV) Non-Current Debt (2015 - 2017) Analysis & Trends
Minerva Neurosciences (NERV) has 3 years of Non-Current Debt data on file, last reported at $1.3 million in Q2 2017.
- Quarterly Non-Current Debt fell 78.69% year-over-year to $1.3 million in Q2 2017, while the trailing twelve-month figure through Jun 2017 was $1.3 million (down 78.69% YoY) and the FY2016 annual result came in at $3.8 million, down 54.83% from the prior year.
- Non-Current Debt fell to $1.3 million in Q2 2017, from $2.6 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $9.6 million in Q3 2015 to a low of $1.3 million in Q2 2017.
- A 3-year average of $6.3 million and a median of $6.8 million in 2016 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2016 — Non-Current Debt fell 22.74% — and 2017, when it tumbled 78.69%.
- Tracing NERV's Non-Current Debt over 3 years: stood at $8.5 million in 2015, then sank by 54.83% to $3.8 million in 2016, then plunged by 65.47% to $1.3 million in 2017.
- The last three Non-Current Debt figures came in at $1.3 million (Q2 2017), $2.6 million (Q1 2017), and $3.8 million (Q4 2016), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 882.16 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 8.96 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Minerva Neurosciences | 207.37 Mn | 207.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2017 | 1.33 Mn |
| Mar 31, 2017 | 2.60 Mn |
| Dec 31, 2016 | 3.84 Mn |
| Sep 30, 2016 | 5.05 Mn |
| Jun 30, 2016 | 6.23 Mn |
| Mar 31, 2016 | 7.38 Mn |
| Dec 31, 2015 | 8.50 Mn |
| Sep 30, 2015 | 9.61 Mn |
| Jun 30, 2015 | 8.70 Mn |
| Mar 31, 2015 | 9.55 Mn |